EDX-MEDICAL-GROUP
2.9.2024 08:01:25 CEST | Business Wire | Press release
EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, announces today it has signed a distribution agreement with Caris Life Sciences® (Caris), a leading US-based next-generation AI TechBio and precision medicine company.
Under the agreement, EDX Medical and Caris will work together on a mutually exclusive basis in the United Kingdom (UK) and Nordic countries for a minimum of three years to distribute Caris’ portfolio of advanced and comprehensive molecular profiling services for clinical and research use.
Caris’ best-in-class molecular profiling, combined with proprietary artificial intelligence, enables physicians to make more precise and individualized cancer treatment decisions. This profiling approach assesses DNA, RNA, and proteins, revealing a molecular blueprint that identifies treatment options specific to each patient’s cancer. Caris has developed one of the world's largest and most informative platform for cancer analysis, featuring the most advanced tumour profiling available, including Whole Exome and Whole Transcriptome Sequencing across over 23,000 genes. By analysing biomarkers found in tumours, Caris helps healthcare providers make informed choices for personalised care.
Caris’ solid tumour and liquid (blood) biopsy molecular profiling services, as well as AI solutions, will be available exclusively via EDX Medical immediately in the UK, Sweden, Denmark, Norway and Finland, with additional regions and products to follow.
Professor Sir Chris Evans, OBE, founder of EDX Medical, said: “The signing of this agreement signifies a further major step forward in our strategy to provide clients with access to world-class diagnostic tools and services that can change the detection, treatment and outcome of illness for patients.
“The pace of scientific advancement is such that for a patient with cancer who may only be able to provide one sample and urgently needs to start optimal treatment, reviewing their whole exome and transcriptome rather than a smaller selection of genes limited by current knowledge is clearly the most robust clinical approach. We could not wish for a better partner in this field than Caris.”
Dr Mike Hudson, CEO of EDX Medical, said: “EDX Medical and Caris are both pioneer companies unified by their focus on providing doctors with access to the best biological information possible from valuable human samples. We are proud to have been selected by Caris to play a key role in jointly bringing these incredibly useful cancer tumour profiling services to the UK and key areas of Europe.”
Dr David Spetzler, MS, PhD, MBA, Caris Life Sciences President, said: “Caris is pleased to partner with EDX Medical to distribute our molecular profiling services within the United Kingdom and Nordic countries. This collaboration aligns with Caris’ goal of enabling clinicians worldwide to make the best individualised treatment choices for their patients and ultimately helping to improve patient outcomes.”
Notes for Editors:
About EDX Medical Group
EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX). The Company operates its own facilities in Cambridge and Oxford, UK, and provides doctors, hospitals and insurers/payers with access to a portfolio of innovative clinical diagnostics products and services. www.edxmedical.com.
About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition.
Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S., Europe, Asia and other international markets. CarisLifeSciences.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240901077038/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Onera Health and VitalAire Strategic Collaboration Closes the Gap Between Home Sleep Diagnostics and Sleep Apnea Therapy in Germany10.11.2026 14:55:00 CET | Press release
The Onera hPSG® solution meets the VitalAire homecare therapy network, giving physicians a faster path from diagnosis to treatment while patients retain full freedom to choose their homecare provider Onera Health, a leader in transforming sleep medicine, and VitalAire, the German homecare subsidiary of Air Liquide Healthcare, announced a collaboration to connect gold standard home-based sleep polysomnography diagnostics with sleep apnea therapy for patients across Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110805161/en/ Ruben de Francisco (left), Founder and CEO of Onera Health, with Boyd Papprott (right), Director of Sales, Marketing & Product Management, Respiratory, at VitalAire Germany, at the DGSM 2026 conference in Wiesbaden. Access to in-lab polysomnography in Germany is limited, forcing patients to often wait a long time for a diagnosis. This collaboration lets physicians order a home PSG online for p
Sparxity Closes Series A, Bringing Total Funding to $90M10.11.2026 14:00:00 CET | Press release
Strategic funding accelerates next-generation sparse-native AI computing, building upon an existing commercial ecosystem and proven silicon Sparxity, a leader in sparse-native computing, today announced the close of its Series A, bringing cumulative funding secured by its team to $90M. The round was led by ICM HPQC Fund and joined by investors such as Lockheed Martin Ventures, GlobalFoundries, GS Futures, Cloudberry Ventures, TGFS and the EIC Fund. The financing also includes angel investments from TIME100 AI leaders Richard Socher (Recursive Superintelligence) and Nancy Xu (Salesforce-acquired Moonhub), alongside continued support from Atlantic and Silicon Catalyst. The funding will accelerate the development of specialized chips for fine-grained dynamic sparsity, targeting up to 44× faster AI inference in ultra-sparse models, bringing greater energy efficiency by computing only what matters. This press release features multimedia. View the full release here: https://www.businesswire.
Transition Industries Selects Technip Energies as PMC Partner for Pacifico Mexinol Ultra-Low Carbon Methanol Project10.11.2026 14:00:00 CET | Press release
Transition Industries announces the selection of Technip Energies as its Project Management Consultancy (PMC) partner for the Pacifico Mexinol project, located in Sinaloa, Mexico, which is expected to become the world's largest ultra-low carbon chemical production facility. Once operational, the facility will produce annually approximately 350,000 metric tons of RFNBO (Renewable Fuel of Non-Biological Origin) methanol and 1.8 million metric tons of ultra-low carbon methanol from natural gas with carbon capture, helping meet growing global demand through a lower-carbon production model. “We are pleased that Technip Energies has joined the project team and will bring their global project management expertise to our landmark industrial development project in Mexico. Technip Energies was selected for their project management expertise, technical know-how and execution capabilities,” says Diego Martinez, Transition Industries Chief Operating Officer. The project will use existing infrastruc
Telia Estonia trials Adtran 50G PON technology to prepare for next-generation broadband services10.11.2026 14:00:00 CET | Press release
News summary: Telia Estonia is preparing its fiber network to support the next generation of residential and business broadband services Trial of Adtran’s 50G PON solution establishes a practical path to higher-capacity access over existing infrastructure Project will validate how 50G PON can operate alongside GPON and XGS-PON services, enabling phased network upgrades Adtran today announced that Telia Estonia, part of Nordic and Baltic telecommunications operator Telia Company, is trialing its 50G PON technology as the next step in the evolution of its fiber broadband infrastructure. Building on its deployment of Adtran’s fiber access platform, the proof of concept (PoC) will evaluate how 50G PON can coexist with existing GPON and XGS-PON services on a common network infrastructure. The trial will help Telia Estonia prepare for future residential and business connectivity requirements while providing a practical framework for introducing higher-capacity services as market needs develo
Vasion® Fall Release Eliminates Dark Documents and Makes Operational Documents AI Ready10.11.2026 14:00:00 CET | Press release
New release puts AI agents, workflows and print into one control center for IT IT-Governed Document AI: Vasion Intelligence (beta) lets IT set guardrails up front while empowering users to easily create human in the loop workflows. Zero Trust Gap: A survey of 500+ U.S. IT leaders reveals print ranks last in Zero Trust coverage at just 16%. Live at Microsoft Ignite: Demos and benchmarking will run November 17–21 at Booth 5509. Vasion, the Intelligent Document Automation company, announced its fall release, which captures the context behind operational documents and makes them ready for AI without IT giving up control. Vasion will demonstrate it at Microsoft Ignite, November 17-21, in San Francisco, booth 5509. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110362305/en/ Vasion® Fall Release Eliminates Dark Documents and Makes Operational Documents AI Ready “Every company runs on operational documents: the invoices, claims,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom